Boehringer Ingelheim Biopharmaceuticals GmbH sell "Drug Substance Manufacturing - Microbial Fermentation"

Name: Boehringer Ingelheim Biopharmaceuticals GmbH sell "Drug Substance Manufacturing - Microbial Fermentation"
Brand: Boehringer Ingelheim Biopharmaceuticals GmbH
Availability: InStock

Boehringer Ingelheim Biopharmaceuticals GmbH

Fabricant sous Contrat (CMO) · Services de sous-traitance & d’externalisationGermany

Informations de base

221

3.7(67)

Catégorie

Services Biopharmaceutiques

Sous-catégorie & Sous-sous-catégorie

Biofabrication / Services de Fabrication à Façon

Type de transaction

Vendre

Nom du service

Drug Substance Manufacturing - Microbial Fermentation

Prestataire(s) de services

Boehringer Ingelheim Biopharmaceuticals GmbH - Germany.

Spécifications

Système d'expression: Fermentation microbienne (systèmes d'expression plasmidique pour E. coli, levure et Pseudomonas), deux lignes flexibles de 6 000 L
Application: Repliement protéique, HPLC à grande échelle, modifications chimiques pour prolonger la demi-vie des molécules, et services de purification uniquement pour protéines recombinantes
Norme de certification: Installations GMP à grande échelle agréées par l'EMA, la FDA et le MHLW pour l'approvisionnement clinique et commercial mondial
Pays d'origine: Vienne, Autriche

Autres informations

Description supplémentaire:

This multi-licensed facility offers 12,000 L of commercial microbial fermentation capacity across two flexible 6,000 L trains, operating large-scale GMP facilities licensed by the EMA, FDA and MHLW for global clinical and commercial supply. Capabilities include protein refolding, large-scale HPLC, explosion-proof units, chemical modifications to extend molecule half-life, purification-only services for recombinant proteins, several plasmid-based expression systems for E. coli, yeast and Pseudomonas, process and analytical development, and GMP batch-release testing, manufacturing Fab fragments, peptide hormones, plasmid DNA, scaffolds, recombinant proteins, enzymes and recombinant vaccines such as virus-like particles from its Vienna, Austria facility, having brought 20 microbial biopharmaceuticals to market with partners.